Advanced Search
XU Qian, ZHU Shu-chai, CAO Yan-kun, SONG Chang-liang, LI You-mei, SHI Gao-feng. Comparison of Pathological T-staging with Gross Tumor Volume (GTV) of Esophageal Cancer by CT Scanning[J]. Cancer Research on Prevention and Treatment, 2009, 36(05): 432-434. DOI: 10.3971/j.issn.1000-8578.2009.05.020
Citation: XU Qian, ZHU Shu-chai, CAO Yan-kun, SONG Chang-liang, LI You-mei, SHI Gao-feng. Comparison of Pathological T-staging with Gross Tumor Volume (GTV) of Esophageal Cancer by CT Scanning[J]. Cancer Research on Prevention and Treatment, 2009, 36(05): 432-434. DOI: 10.3971/j.issn.1000-8578.2009.05.020

Comparison of Pathological T-staging with Gross Tumor Volume (GTV) of Esophageal Cancer by CT Scanning

More Information
  • Received Date: December 08, 2008
  • Revised Date: March 22, 2009
  • Objective To explore relationship between the pathological T-staging and the gross tumor volume (GTV) of esophageal cancer by CT scanning and provide the reference for clinical T-stageing of esophageal carcinoma. Methods Two hundred and eight patients with esophageal cancer have received operation from January 2005 to December. They all were checked by CT scanning on chest before operation. GTV-T target was delineated by applying 3D radiotherapy system. The largest diameter and the lesion of esophageal affection were measured for each case, and GTV-T volume was calculated. Recorded and measured the lesion length of esophageal cancer in operation. Analyze the relation-ship of the GTV-T volume, the maximum diameter, the length of lesion and the pathological T-staging. Results There was no significant difference between the length of GTV and the lesion length measured by in-operation of esophageal cancer (t=-1.786,P=0.076).The GTV-T volume of T1 stage was significantly different compared with T2, T3, T4 stage (P<0.05), as same between T2 and T3 stage in GTV (P<0.05). But the GTV was not different between T2 and T4 stage, T3 and T4 stage. About the lesion length and the maximum diameter, T1 stage was significantly different with T3, T4 stage (P<0.05). There was no difference between T1 and T2 stage. Furthermore, T2 stage was dramatically different with T3 and T4 stage in the maximum diameter and length of esophageal lesion (P<0.05), but no difference between T3 and T4 stage. Conclusion The later pathological T-stage is, the larger tumor volume is. The GTV-T volume of esophageal cancer might be used as guidance of esophageal cancer clinical T stage.
  • Related Articles

    [1]YAO Weirong, WAN Huiping, YU Yanmin, LUO Lifang, ZHANG Xiquan, TANG Zhimou. Effects of Stability Plasma Concentration of 5-Fu and Docetaxel on Adverse Events and Short Term Effect after 5-Fu and Docetaxel Chemotherapy[J]. Cancer Research on Prevention and Treatment, 2014, 41(01): 53-56. DOI: 10.3971/j.issn.1000-8578.2014.01.012
    [2]Yang Liuzhong, Cui Yanhui, Kou Weizheng, Kou Xiaoge, Miao Zhanhui, Niu Hongrui. Clinical Observation on Thalidomide Accompanied Docetaxel in Chemotherapy Patients with Advanced Non-small Cell Lung Cancer As Second-line Chemotherapy[J]. Cancer Research on Prevention and Treatment, 2012, 39(03): 324-328. DOI: 10.3971/j.issn.1000-8578.2012.03.020
    [3]Liao Jiahua, Lin Huanxin, Sun Jian, Sun Rui, Guo Ling. Chrono-chemotherapy of Docetaxel in Nude Mice Bearing Human Nasopharyngeal Carcinoma[J]. Cancer Research on Prevention and Treatment, 2012, 39(01): 18-22. DOI: 10.3971/j.issn.1000-8578.2012.01.005
    [4]CAI Yong-guang, LI Ming, XIE Xin. Clinical Observation of Docetaxel or Gemcitabine Combine with Cisplatin in Treatment of Patients with Advanced Non-small Cell Lung Cancer[J]. Cancer Research on Prevention and Treatment, 2010, 37(11): 1308-1311. DOI: 10.3971/j.issn.1000-8578.2010.11.027
    [5]CHEN Kun, LIN Qiang, ZHAO Yan- nan, BI Yan-hua, WANG Na, LIU Yue-e. Comparison of Gemcitabine and Paclitaxel Combined with Fractionation-dose Cisplatin in Treatment of Untreated Advanced Non-small Cell Lung Cancer[J]. Cancer Research on Prevention and Treatment, 2010, 37(06): 709-711. DOI: 10.3971/j.issn.1000-8578.2010.06.028
    [6]HAN Xiao, WANG Zhe-hai, GUO Jun, LIU Lin, LIU Li-yan. Clinical Observation of Docetaxel Combined with Vinorelbine as Second Line Treatment for Patients with Advanced Gastric Cancer[J]. Cancer Research on Prevention and Treatment, 2010, 37(06): 705-708. DOI: 10.3971/j.issn.1000-8578.2010.06.027
    [7]FU Xiao-min, WANG Jing, ZHANG Hui, BAO Ai-hua. Clinical Research for Docetaxel Plus Cisplatin in Untreated Adwanced Non-small Cell Lung Cancer[J]. Cancer Research on Prevention and Treatment, 2010, 37(02): 205-208. DOI: 10.3971/j.issn.1000-8578.2010.02.022
    [8]ZHAN Shan-shan, WANG Zhi-gang, FU Mu-chang. Docetaxel Combined with Intraperitoneal Fluorouracil Chemotherapy in Treatment of Advanced Gastric Cancer[J]. Cancer Research on Prevention and Treatment, 2009, 36(02): 153-155.
    [9]HUANG Cheng-suo, WANG Zhe-hai, CHEN zhen. Clinical Study of Docetaxel Combined with Cisplatin and Fluorouracil in Treatment of Advanced Esophageal Cancer[J]. Cancer Research on Prevention and Treatment, 2008, 35(06): 436-438. DOI: 10.3971/j.issn.1000-8578.2322
    [10]LIU Zhi-hui, ZHOU Wen-xian, LI Yong-qiang, HU Xiao-hua. Gemcitabine Plus Carboplatin as Second-line Chemotherapy in Patients with Advanced Nasopharyngeal Carcinoma[J]. Cancer Research on Prevention and Treatment, 2007, 34(12): 962-964. DOI: 10.3971/j.issn.1000-8578.1703

Catalog

    Article views (2277) PDF downloads (473) Cited by()

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return